The Directory of Open Access Journals
DOAJ Logotype
Open
Global
Trusted
Main actions
Support
Institutions and libraries
Publishers
Institutional and library supporters
Apply
Application form
Guide to applying
The DOAJ Seal
Transparency & best practice
Publisher information
Licensing & copyright
Search
Menu
Secondary actions
Search
Journals
Articles
Documentation
API
OAI-PMH
Widgets
Public data dump
OpenURL
XML
Metadata help
Preservation
About
About DOAJ
DOAJ at 20
DOAJ team
Ambassadors
Advisory Board & Council
Volunteers
News
Support
Institutions and libraries
Publishers
Institutional and library supporters
Apply
Application form
Guide to applying
The DOAJ Seal
Transparency & best practice
Publisher information
Licensing & copyright
Login
Login
Quick search
Close
×
Journals
Articles
Search by keywords:
In the field:
In all fields
Title
ISSN
Subject
Publisher
Country of publisher
Search
Frontiers in Oncology
(Mar 2023)
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
Zsuzsanna Nagy,
Zsuzsanna Nagy,
Zsuzsanna Nagy,
Rinath Jeselsohn,
Rinath Jeselsohn,
Rinath Jeselsohn,
Rinath Jeselsohn
Affiliations
Zsuzsanna Nagy
Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
Zsuzsanna Nagy
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
Zsuzsanna Nagy
Department of Medicine, Harvard Medical School, Boston, MA, United States
Rinath Jeselsohn
Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
Rinath Jeselsohn
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
Rinath Jeselsohn
Department of Medicine, Harvard Medical School, Boston, MA, United States
Rinath Jeselsohn
Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
DOI
https://doi.org/10.3389/fonc.2023.1155540
Journal volume & issue
Vol. 13
Abstract
Read online
No abstracts available.
Keywords
breast cancer
estrogen receptor
ESR1 fusion
endocrine therapy resistance
SERD
WeChat QR code
Close